天士力(600535.SH):上半年預虧3.59億元-4.21億元
格隆匯7月14日丨天士力(600535.SH)公佈,經財務部門初步測算,預計2022年上半年度實現歸屬於上市公司股東的淨利潤為-4.209億元至-3.59億元,與上年同期相比,同比減少136%到142%。
預計2022年上半年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤為4.46億元到5.08億元,與2021年同期相比,同比減少18%到28%。
業績變化的主要原因為非經營性損益影響:1、公司2021年上半年金融資產公允價值上升10809.14萬元,2022年上半年度持有的金融資產公允價值有所下降(主要為I-MAB和科濟藥業公允價值分別下降78368.76萬元和11090.14萬元),本期公允價值變動損益較上年同期減少107,348.81萬元;2、本期歌禮股權處置收益為421.34萬元,去年同期公司處置I-MAB部分股權獲得收益24,570.11萬元,較上年同期減少24,148.77萬元。
業績變化的主營業務影響主要系引進研發項目本期支付大額許可費用:公司控股子公司天士力生物醫藥股份有限公司獲得美國Sutro Biopharma,Inc.的獨家許可,在區域內(即中國大陸、香港及澳門特別行政區、台灣地區)獨家開發和商業化一種靶向葉酸受體α(FRα)的抗體偶聯藥物,本期支付許可首付款2500萬美元,含税費摺合人民幣1.6858億元。剔除該影響因素,公司主營業務保持穩定,歸屬於上市公司股東的扣除非經常性損益的淨利潤與去年同期相比,變化幅度處於基本持平到上升9%的區間範圍內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.